세계 IV 및 경구 철분제 시장 규모는 2023년 76억 6,000만 달러에 달했습니다. 이 시장은 2029년까지 연평균 13.47%의 강력한 성장세를 보일 것으로 예상됩니다. 이러한 빠른 성장의 주요 요인은 전 세계적으로 철 결핍증(ID) 및 철 결핍성 빈혈(IDA)의 유병률 증가와 효과적인 치료 옵션에 대한 환자들의 인식이 높아진 것이 주요 요인입니다. 만성 신장 질환(CKD), 심부전, 위장 장애, 암 등 철분 결핍을 유발할 수 있는 만성 질환, 특히 수술 환자에서 철분 결핍을 유발할 수 있는 만성 질환의 발생이 증가하고 있는 것도 시장 확대에 기여하고 있습니다.
시장 성장을 가속하는 주요 요인으로는 덱스트런프리 철분 치료제에 대한 수요 증가와 투석 및 비투석 신장 환자의 철분제 수요 증가를 들 수 있습니다. 또한, 더 넓은 적응증과 더 나은 치료 결과를 목표로 임상시험 중인 최신 세대의 정맥주사 및 경구 철분제의 개발도 시장 성장의 원동력이 되고 있습니다.
Vifor Pharma와 같은 시장 리더들은 Ferinject(미국에서는 Injectafer로 판매)와 Venofer와 같은 제품으로 큰 기여를 하고 있으며, 특히 투석 환자들 사이에서 큰 인기를 얻고 있습니다. 처방약과 일반의약품으로 구성된 경구 철분제 부문은 정맥주사용 철분제에 비해 완만하지만 꾸준히 성장하고 있으며, 비용 효율성이 높아 신흥국과 저소득 국가에서 큰 성장세를 보이고 있습니다.
시장 성장은 선진국뿐만 아니라 철분 결핍이 심각한 건강 문제로 대두되고 있는 아시아, 아프리카, 라틴아메리카의 신흥국에서도 두드러진 성장세를 보이고 있습니다. 이러한 성장은 병원 약국의 업무 혁신과 소매점의 참여로 인해 더욱 가속화되고 있으며, 소비자의 접근성과 인지도를 높이고 있습니다.
병원 약국 부문은 철분제에 특화된 서비스를 제공하기 때문에 성장이 예상됩니다. 동시에, 소매점은 즉각적인 제품 공급과 전문가의 지도를 받을 수 있기 때문에 계속해서 중요한 역할을 하고 있으며, CKD 환자의 철분 결핍 유병률은 약 70%로 추정되며, 정맥 및 경구 철분 치료의 중요한 필요성을 강조하고 있습니다.
이 보고서는 세계 IV 및 경구 철분제 시장을 조사했으며, 시장 개요와 함께 투여 경로별, 환자 그룹별, 유통 채널별, 용도별, 지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
목차
제1장 수액 및 경구 철분제 시장 개요
제2장 수액 및 경구 철분제 시장
제3장 수액 및 경구 철분제 시장 예측 매출(2023년-2029년;10억 달러)
- 세계 : 투여 경로별 예측 매출(2023년-2029년;10억 달러)
- 세계 : 환자 그룹별 예상 매출(2023년-2029년;10억 달러)
- 세계 : 유통 채널별 예상 매출(2023년-2029년;10억 달러)
- 세계 : 용도별 예측 매출(2023년-2029년;10억 달러)
제4장 주요 지역 개요
- 북미
- 미국
- 캐나다
- 유럽
- 독일
- 영국
- 프랑스
- 이탈리아
- 스페인
- 아시아태평양
- 일본
- 중국
- 호주
- 라틴아메리카
- 브라질
- 멕시코
- 아르헨티나
- 중동 및 아프리카
- 터키
- 남아프리카공화국
- 사우디아라비아
제5장 수액 및 경구 철분제 시장 전망과 기회
- IV 및 경구 철분제 시장 기회와 동향
- IV 및 경구 철분제 시장 성장 촉진요인
- IV 및 경구 철분제 시장 성장 억제요인
제6장 수액 및 경구 철분제 업계 개요
- IV 및 경구 철분제 시장 - 경쟁 구도
- IV 및 경구 철분제 시장 - 주요 벤더 개요
- IV 및 경구 철분제 시장 - 기타 저명한 벤더
- IV 및 경구 철분제 시장 - 주요 전략적 추천 사항
제7장 부록
LSH
The global IV and Oral Iron Drugs market, valued at $7.66 billion in 2023, will experience robust growth by 2029, expanding at a CAGR of 13.47%. This surge is primarily driven by the increasing prevalence of Iron Deficiency (ID) and Iron Deficiency Anemia (IDA) globally, coupled with a heightened awareness among patients about effective treatment options. The market's expansion is further propelled by the rising occurrence of chronic diseases such as Chronic Kidney Disease (CKD), heart failure, gastrointestinal disorders, and cancer, which can lead to iron deficiency, particularly in surgical patients.
Key factors fueling market growth include the growing demand for dextran-free iron therapeutics and the rising need for iron drugs among dialysis and non-dialysis kidney patients. The market also benefits from the development of investigational latest generation IV & oral iron drugs with broader indications and improved treatment outcomes.
Market leaders like Vifor Pharma are significantly contributing with products such as Ferinject (marketed as Injectafer in the US) and Venofer, which are gaining traction, especially among dialysis patients. The oral iron drug segment, comprising both prescription and OTC preparations, is expanding steadily, although slower than IV iron drugs, with significant growth in emerging and low-income countries due to their cost-effectiveness.
The market's growth is not just confined to developed nations; it's also significant in developing countries across Asia, Africa, and Latin America, where iron deficiency poses a severe health challenge. This growth is further augmented by innovations in hospital pharmacy practice and retail store involvement, facilitating accessibility and awareness among consumers.
The hospital pharmacies segment is expected to grow due to their specialized services in iron medicines. At the same time, retail stores continue to play a crucial role due to immediate product availability and expert guidance. The prevalence of iron deficiency in CKD patients, which is estimated to be around 70%, highlights the critical need for iron therapy with IV and oral iron drugs.
As the global IV & oral iron drugs market evolves, key vendors like Vifor Pharma, Daiichi Sankyo Group, AMAG Pharmaceuticals, and others focus on product innovations and expanded label approvals to meet the growing demands and adapt to new patient groups. The market, characterized by the presence of global, regional, and local players, is highly competitive with a wide array of branded and generic drug offerings.
KEY HIGHLIGHTS:
- The IV & oral iron drugs market represents a rapidly growing and most effective category of therapeutics that helps individuals with ID & IDA to improve their quality of life.
- By route of administration, the intravenous (IV) segment was valued at $4.40 billion in 2023. This growth mainly results from the expected launch of branded IV iron drugs in new markets and expanded indication approval for existing commercially available brands. One of the primary reasons for this significant growth rate is the increased uptake of branded IV drugs in the US and European markets.
- By patient group, the adult segment is going to witness notable growth during the forecast period. In 2023, the adult segment accounted for 83.33% of the global IV & oral iron drugs market. The segment is dominating the market due to the higher incidence/ prevalence of ID and IDA among elderly people across the world.
- By distribution channel, the hospital pharmacies segment is expected to grow at a significant CAGR. Hospital pharmacies offer iron drugs with adequate discounts and rebates. Thus offering a cost-effective way to minimize the burden on patients and healthcare systems.
- By application, In 2023, the nephrology segment accounted for 60.84% of the global IV & oral iron drugs market. The market for iron drugs in nephrology is increasing faster, and the trend is likely to continue during the forecast period due to the rising prevalence of CKD worldwide. The segment accounted for the largest market share owing to the increasing uptake of iron drugs to treat CKD.
- CSL Vifor, Covis Pharmaceuticals, Daiichi Sankyo, Akebia Therapeutics, Shield Therapeutics, and others are some of the leading players currently dominating the global IV & Oral iron drugs market. The major players focus on strategic acquisitions and collaborations with emerging players to enter the IV & Oral Iron Drugs market and to gain access to commercially launched products.
REPORT HIGHLIGHTS
PRODUCT SEGMENTATION & FORECAST
- Route of Administration
- Intravenous
- Oral
- Patient Group
- Adults
- Pediatrics
- Distribution Channel
- Hospital Pharmacies
- Offline Retail Pharmacies
- Online Channels
- Application
- Nephrology
- Obstetrics & Gynaecology
- Surgery
- Gastroenterology
- Oncology
- Heart Failure
- MARKET STRUCTURE
- Market Dynamics
- Competitive Landscape of IV & Oral Iron Drugs Market
- Key Vendors
- Other Prominent Vendors
- APPENDIX
- Research Methodology
- Abbreviations
- About Arizton
VENDORS LIST
- CSL Vifor
- Daiichi Sankyo
- Covis Pharmaceuticals
- Akebia Therapeutics
- Shield Therapeutics
- Pharmacosmos
- AbbVie
- Sanofi
- AOP Orphan Pharmaceuticals
- Azad Pharmaceuticals
- Pfizer
- Ciron Drugs & Pharmaceuticals
- Rockwell Medical
- Salveo Lifecare
- Sunny Pharmaceuticals
- Zydus LifeSciences
- Nippon Shinyaku
- Alinter Group
- Alora Pharmaceuticals
- DSE Healthcare
- GSK plc
TABLE OF CONTENTS
CHAPTER - 1: IV & Oral Iron Drugs Market Overview
- Executive Summary
- Key Findings
CHAPTER - 2: IV & Oral Iron Drugs Market
- GLOBAL: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
CHAPTER - 3: IV & Oral Iron Drugs Market Segmentation Data
- GLOBAL: Projected Revenue by Route of Administration (2023-2029; $Billions)
- Intravenous
- Oral
- GLOBAL: Projected Revenue by Patient Group (2023-2029; $Billions)
- Adults
- Pediatrics
- GLOBAL: Projected Revenue by Distribution Channel (2023-2029; $Billions)
- Hospital Pharmacies
- Offline Retail Pharmacies
- Online Channels
- GLOBAL: Projected Revenue by Application (2023-2029; $Billions)
- Nephrology
- Obstetrics & Gynecology
- Surgery
- Gastroenterology
- Oncology
- Heart Failure
CHAPTER - 4: Key Regions Overview
- North America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
- Projected Revenue of IV & Oral Iron Drugs Market in US
- Projected Revenue of IV & Oral Iron Drugs Market in Canada
- Europe: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
- Projected Revenue of IV & Oral Iron Drugs Market in Germany
- Projected Revenue of IV & Oral Iron Drugs Market in UK
- Projected Revenue of IV & Oral Iron Drugs Market in France
- Projected Revenue of IV & Oral Iron Drugs Market in Italy
- Projected Revenue of IV & Oral Iron Drugs Market in Spain
- APAC: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
- Projected Revenue of IV & Oral Iron Drugs Market in Japan
- Projected Revenue of IV & Oral Iron Drugs Market in China
- Projected Revenue of IV & Oral Iron Drugs Market in Australia
- Latin America: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
- Projected Revenue of IV & Oral Iron Drugs Market in Brazil
- Projected Revenue of IV & Oral Iron Drugs Market in Mexico
- Projected Revenue of IV & Oral Iron Drugs Market in Argentina
- Middle East & Africa: Projected Revenue of IV & Oral Iron Drugs Market (2023-2029; $Billions)
- Projected Revenue of IV & Oral Iron Drugs Market in Turkey
- Projected Revenue of IV & Oral Iron Drugs Market in South Africa
- Projected Revenue of IV & Oral Iron Drugs Market in Saudi Arabia
CHAPTER - 5: IV & Oral Iron Drugs Market Prospects & Opportunities
- IV & Oral Iron Drugs Market Opportunities & Trends
- IV & Oral Iron Drugs Market Drivers
- IV & Oral Iron Drugs Market Constraints
CHAPTER - 6: IV & Oral Iron Drugs Industry Overview
- IV & Oral Iron Drugs Market - Competitive Landscape
- IV & Oral Iron Drugs Market - Key Vendor Profiles
- IV & Oral Iron Drugs Market - Other Prominent Vendors
- IV & Oral Iron Drugs Market - Key Strategic Recommendations
CHAPTER - 7: Appendix
- Research Methodology
- Abbreviations
- About Arizton
